Publication: 3167

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer
      QxMD      Google Scholar   
Citation:
JNCI Cancer Spectr vol 4 (3)
Year:
2020
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
collection
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
9
Parents:
2673   2810   2819  
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
Eli Lilly and Company, Pfizer, Bristol-Myers Squibb, Sanofi  
Grants:
U10CA180821, U10CA180882, R01 CA210509-01A1; UG1CA232760, U10CA180888, U10CA180835 (SWOG), U10CA180863, CCSRI 021039 (CCTG), U10CA180868; U24CA196067 (NRG), U24CA196171  
Corr. Author:
 
Authors:
                             
Networks:
LAPS-IL036, LAPS-MN026, LAPS-OH007, MCRC   
Study
NCCTG-N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Article